| Recruiting | Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemi NCT07073794 | Mayo Clinic | Phase 2 |
| Recruiting | Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patie NCT07025369 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Withdrawn | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Pa NCT06094842 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation NCT05487846 | Thomas Jefferson University | N/A |
| Recruiting | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patie NCT05869682 | City of Hope Medical Center | Phase 2 |
| Recruiting | Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network NCT05627219 | Thomas Jefferson University | — |
| Active Not Recruiting | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study NCT05960578 | University of Washington | Phase 2 |
| Recruiting | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcino NCT06205316 | Mayo Clinic | Phase 3 |
| Recruiting | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Pr NCT05691465 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer NCT06129851 | University of Kansas Medical Center | Phase 2 |
| Recruiting | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer NCT06173362 | University of California, Davis | Phase 2 |
| Suspended | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prost NCT05445609 | Emory University | Phase 2 |
| Active Not Recruiting | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Pr NCT05241860 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer NCT05034562 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoC NCT05168618 | University of Utah | Phase 2 |
| Terminated | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05037500 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients NCT05045066 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate C NCT04455750 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion NCT04976257 | Ryan Kohlbrenner, MD | EARLY_Phase 1 |
| Active Not Recruiting | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer NCT04716725 | Thomas Hope | Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Ca NCT04915508 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prosta NCT04734730 | City of Hope Medical Center | Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03709550 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT04471974 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of NCT04592237 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemica NCT04585932 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study NCT04447703 | Thomas Jefferson University | N/A |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor M NCT05054296 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer NCT04190446 | Mayo Clinic | Phase 2 |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Active Not Recruiting | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer NCT03873805 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436 | Roswell Park Cancer Institute | Phase 1 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Pros NCT03517969 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response NCT03581500 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small NCT03582475 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prosta NCT03678025 | SWOG Cancer Research Network | Phase 3 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer NCT04050215 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant NCT03360721 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Genetic Testing for Men With Metastatic Prostate Cancer NCT03503097 | University of Washington | — |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |